Medicine: A new drug against the flu
Nature Cell Biology 3, pp 301 - 305
As we all know, unless you were prudent and got a vaccine earlier in the season, there's not much to do about the flu once you're
infected with the virus apart from having aspirin, vitamins and hot tea and lying in bed for a couple of days, waiting for your
immune system to win the battle against the virus.
Stephan Ludwig and his colleagues at Wuerburg University in Germany now report on pages 301-305 of the March issue of
Nature Cell Biology how inhibitors of the MAP kinases could be used to prevent viral spreading.
Once it infects a cell, the influenza A virus uses the host cell machinery to proliferate: its genetic material is
replicated and translated into viral proteins by the cellular machinery. Viral RNA and viral proteins are then assembled
into viral particles, and eventually released from the host cell into the extracellular space, where the newly produced
viral particles can infect other cells, starting another cycle of viral replication…
Ludwig and colleagues found inhibition of the Raf kinase to result in inhibition of viral propagation. Why is Raf
activity required for viral spreading? When Raf activity is blocked, production of viral material by the host cell is
unimpaired, but it is retained in the nucleus and thus cannot propagate to other cells.
But the Raf/MEK/ERK kinases have many other cellular targets, regulating a number of different cellular events
such as cell proliferation, cellular differentiation and cell death. So before it can be envisaged to use these
inhibitors as anti-flu drugs, means need to be developed to specifically target the drugs to viral infected cells
if one is to avoid dramatic side effects.